RPS6KA3 and melanoma: Along with a MAPK pathway hyperactivation, BRAF-mutated melanoma cells exhibit increased RSK activity and can be effectively targeted by RSK inhibition particularly in the case of MAPK pathway inhibitor resistance [18].